$310 Million is the total value of Krensavage Asset Management, LLC's 15 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 18.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | BIOVERATIV INC | $40,651,000 | – | 746,445 | +100.0% | 13.11% | – | |
| GILD | Buy | GILEAD SCIENCES INC | $36,474,000 | +21.3% | 537,021 | +27.9% | 11.76% | +9.1% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $33,835,000 | -4.3% | 1,098,524 | +4.1% | 10.91% | -14.0% |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $31,780,000 | -18.2% | 234,743 | -13.3% | 10.25% | -26.4% |
| SCMP | Buy | SUCAMPO PHARMACEUTICALS-CL A | $30,835,000 | +22.1% | 2,803,138 | +50.4% | 9.94% | +9.8% |
| OFIX | Buy | ORTHOFIX INTERNATIONAL NV | $26,605,000 | +13.9% | 697,378 | +8.0% | 8.58% | +2.5% |
| MRK | Buy | MERCK & CO. INC. | $24,451,000 | +64.2% | 384,806 | +52.2% | 7.88% | +47.7% |
| HYH | Buy | HALYARD HEALTH INC | $22,266,000 | +6.6% | 584,564 | +3.5% | 7.18% | -4.1% |
| RTIX | Buy | RTI SURGICAL INC | $17,756,000 | +29.6% | 4,438,950 | +5.3% | 5.73% | +16.5% |
| CNMD | Buy | CONMED CORP | $15,823,000 | +9.0% | 356,304 | +8.4% | 5.10% | -2.0% |
| IVC | Buy | INVACARE CORP | $13,692,000 | -4.8% | 1,150,629 | +4.4% | 4.42% | -14.4% |
| AMGN | Sell | AMGEN INC | $11,159,000 | -40.0% | 68,015 | -46.5% | 3.60% | -46.0% |
| AVIR | Buy | AVIRAGEN THERAPEUTICS INC | $1,848,000 | -45.1% | 2,836,326 | +3.6% | 0.60% | -50.6% |
| DRAD | Sell | DIGIRAD CORP | $1,771,000 | -27.2% | 334,179 | -31.3% | 0.57% | -34.5% |
| JNP | Sell | JUNIPER PHARMACEUTICALS INC | $1,155,000 | -29.1% | 243,128 | -16.4% | 0.37% | -36.3% |
| DSCI | Exit | DERMA SCIENCES INC | $0 | – | -891,026 | -100.0% | -1.66% | – |
| Exit | INDIVIOR PLC | $0 | – | -4,650,416 | -100.0% | -6.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.